Am Fam Physician. 2025;111(2):171-172
Author disclosure: No relevant financial relationships.
The MI-Heart Ceramides test is used to determine the risk of adverse cardiovascular events. It assesses various plasma ceramides, a type of complex lipid. There are many different types of ceramides in the body resulting from unstable atherosclerotic plaques. When elevated, ceramides are associated with major adverse cardiovascular events (MACE). The MI-Heart Ceramides test has not been approved by the US Food and Drug Administration.
| Test | Indication | Population | Cost* |
|---|---|---|---|
| MI-Heart Ceramides test | Stratify the risk of major adverse cardiovascular events within the next 1–5 years | Adults 18 years and older with or without existing cardiovascular disease | $180 |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
